Evidence for a common biological basis of the absorption trait, hallucinogen effects, and positive symptoms: Epistasis between 5-HT2a and COMT polymorphisms

Absorption represents a disposition to experience altered states of consciousness characterized by intensively focused attention. It is correlated with hypnotic susceptibility and includes phenomena ranging from vivid perceptions and imaginations to mystical experiences. Based on the assumption that...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of medical genetics. Part B, Neuropsychiatric genetics Vol. 137B; no. 1; pp. 29 - 32
Main Authors Ott, Ulrich, Reuter, Martin, Hennig, Juergen, Vaitl, Dieter
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 05.08.2005
Subjects
Online AccessGet full text
ISSN1552-4841
1552-485X
DOI10.1002/ajmg.b.30197

Cover

Abstract Absorption represents a disposition to experience altered states of consciousness characterized by intensively focused attention. It is correlated with hypnotic susceptibility and includes phenomena ranging from vivid perceptions and imaginations to mystical experiences. Based on the assumption that drug‐induced and naturally occurring mystical experiences share common neural mechanisms, we hypothesized that Absorption is influenced by the T102C polymorphism affecting the 5‐HT2a receptor, which is known to be an important target site of hallucinogens like LSD. Based on the pivotal role ascribed to the prefrontal executive control network for absorbed attention and positive symptoms in schizophrenia, it was further hypothesized that Absorption is associated with the VAL158MET polymorphism of the catechol‐O‐methyltransferase (COMT) gene affecting the dopaminergic neurotransmitter system. The Tellegen Absorption Scale was administered to 336 subjects (95 male, 241 female). Statistical analysis revealed that the group with the T/T genotype of the T102C polymorphism, implying a stronger binding potential of the 5‐HT2a receptor, indeed had significantly higher Absorption scores (F = 10.00, P = 0.002), while no main effect was found for the COMT polymorphism. However, the interaction between T102C and COMT genotypes yielded significance (F = 3.89; P = 0.049), underlining the known functional interaction between the 5‐HT and the dopaminergic system. These findings point to biological foundations of the personality trait of Absorption. © 2005 Wiley‐Liss, Inc.
AbstractList Absorption represents a disposition to experience altered states of consciousness characterized by intensively focused attention. It is correlated with hypnotic susceptibility and includes phenomena ranging from vivid perceptions and imaginations to mystical experiences. Based on the assumption that drug‐induced and naturally occurring mystical experiences share common neural mechanisms, we hypothesized that Absorption is influenced by the T102C polymorphism affecting the 5‐HT2a receptor, which is known to be an important target site of hallucinogens like LSD. Based on the pivotal role ascribed to the prefrontal executive control network for absorbed attention and positive symptoms in schizophrenia, it was further hypothesized that Absorption is associated with the VAL158MET polymorphism of the catechol‐O‐methyltransferase (COMT) gene affecting the dopaminergic neurotransmitter system. The Tellegen Absorption Scale was administered to 336 subjects (95 male, 241 female). Statistical analysis revealed that the group with the T/T genotype of the T102C polymorphism, implying a stronger binding potential of the 5‐HT2a receptor, indeed had significantly higher Absorption scores (F = 10.00, P = 0.002), while no main effect was found for the COMT polymorphism. However, the interaction between T102C and COMT genotypes yielded significance (F = 3.89; P = 0.049), underlining the known functional interaction between the 5‐HT and the dopaminergic system. These findings point to biological foundations of the personality trait of Absorption. © 2005 Wiley‐Liss, Inc.
Absorption represents a disposition to experience altered states of consciousness characterized by intensively focused attention. It is correlated with hypnotic susceptibility and includes phenomena ranging from vivid perceptions and imaginations to mystical experiences. Based on the assumption that drug-induced and naturally occurring mystical experiences share common neural mechanisms, we hypothesized that Absorption is influenced by the T102C polymorphism affecting the 5-HT2a receptor, which is known to be an important target site of hallucinogens like LSD. Based on the pivotal role ascribed to the prefrontal executive control network for absorbed attention and positive symptoms in schizophrenia, it was further hypothesized that Absorption is associated with the VAL158MET polymorphism of the catechol-O-methyltransferase (COMT) gene affecting the dopaminergic neurotransmitter system. The Tellegen Absorption Scale was administered to 336 subjects (95 male, 241 female). Statistical analysis revealed that the group with the T/T genotype of the T102C polymorphism, implying a stronger binding potential of the 5-HT2a receptor, indeed had significantly higher Absorption scores (F = 10.00, P = 0.002), while no main effect was found for the COMT polymorphism. However, the interaction between T102C and COMT genotypes yielded significance (F = 3.89; P = 0.049), underlining the known functional interaction between the 5-HT and the dopaminergic system. These findings point to biological foundations of the personality trait of Absorption.
Absorption represents a disposition to experience altered states of consciousness characterized by intensively focused attention. It is correlated with hypnotic susceptibility and includes phenomena ranging from vivid perceptions and imaginations to mystical experiences. Based on the assumption that drug-induced and naturally occurring mystical experiences share common neural mechanisms, we hypothesized that Absorption is influenced by the T102C polymorphism affecting the 5-HT2a receptor, which is known to be an important target site of hallucinogens like LSD. Based on the pivotal role ascribed to the prefrontal executive control network for absorbed attention and positive symptoms in schizophrenia, it was further hypothesized that Absorption is associated with the VAL158MET polymorphism of the catechol-O-methyltransferase (COMT) gene affecting the dopaminergic neurotransmitter system. The Tellegen Absorption Scale was administered to 336 subjects (95 male, 241 female). Statistical analysis revealed that the group with the T/T genotype of the T102C polymorphism, implying a stronger binding potential of the 5-HT2a receptor, indeed had significantly higher Absorption scores (F = 10.00, P = 0.002), while no main effect was found for the COMT polymorphism. However, the interaction between T102C and COMT genotypes yielded significance (F = 3.89; P = 0.049), underlining the known functional interaction between the 5-HT and the dopaminergic system. These findings point to biological foundations of the personality trait of Absorption.Absorption represents a disposition to experience altered states of consciousness characterized by intensively focused attention. It is correlated with hypnotic susceptibility and includes phenomena ranging from vivid perceptions and imaginations to mystical experiences. Based on the assumption that drug-induced and naturally occurring mystical experiences share common neural mechanisms, we hypothesized that Absorption is influenced by the T102C polymorphism affecting the 5-HT2a receptor, which is known to be an important target site of hallucinogens like LSD. Based on the pivotal role ascribed to the prefrontal executive control network for absorbed attention and positive symptoms in schizophrenia, it was further hypothesized that Absorption is associated with the VAL158MET polymorphism of the catechol-O-methyltransferase (COMT) gene affecting the dopaminergic neurotransmitter system. The Tellegen Absorption Scale was administered to 336 subjects (95 male, 241 female). Statistical analysis revealed that the group with the T/T genotype of the T102C polymorphism, implying a stronger binding potential of the 5-HT2a receptor, indeed had significantly higher Absorption scores (F = 10.00, P = 0.002), while no main effect was found for the COMT polymorphism. However, the interaction between T102C and COMT genotypes yielded significance (F = 3.89; P = 0.049), underlining the known functional interaction between the 5-HT and the dopaminergic system. These findings point to biological foundations of the personality trait of Absorption.
Author Vaitl, Dieter
Hennig, Juergen
Reuter, Martin
Ott, Ulrich
Author_xml – sequence: 1
  givenname: Ulrich
  surname: Ott
  fullname: Ott, Ulrich
  email: Ulrich.Ott@psychol.uni-giessen.de
  organization: Center for Psychobiology and Behavioral Medicine, University of Giessen, Germany
– sequence: 2
  givenname: Martin
  surname: Reuter
  fullname: Reuter, Martin
  organization: Center for Psychobiology and Behavioral Medicine, University of Giessen, Germany
– sequence: 3
  givenname: Juergen
  surname: Hennig
  fullname: Hennig, Juergen
  organization: Center for Psychobiology and Behavioral Medicine, University of Giessen, Germany
– sequence: 4
  givenname: Dieter
  surname: Vaitl
  fullname: Vaitl, Dieter
  organization: Center for Psychobiology and Behavioral Medicine, University of Giessen, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/15965969$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1uEzEUhS1URH9gxxp5xSpT7JnMeIZdlYYU6J9EEN1Ztuc6cbHHw9hpybvwsDhJWyQkkCxdL77vXumcQ7TX-Q4Qek3JMSUkfydu3eJYHheENuwZOqBlmWfjurzZe_qP6T46DOGWkIKUjL1A-7RsqvSaA_Rremda6BRg7QcssPLO-Q5L461fGCUsliKYgL3GcQlYyOCHPpqExEGYOMJLYe1Kmc4voMOgNagYRlh0Le59MNHcAQ5r10fvwns87U2I230S4j0ko8zO5rnY8pOri3mS7NqlE0sTXHiJnmthA7x6mEfo64fpfHKWnV_NPk5OzjM1JjnLmpqyCvKWQltTqhQTdcOIZoQAk0VLWskUrZu2KElFSdXkkqhcV0xqUmsiVHGE3u729oP_sYIQuTNBgbWiA78KvKoJSyZN4JsHcCUdtLwfjBPDmj_mmYDRDlCDD2EA_QchfFMX39TFJd_WlfD8L1yZKDbxbtK1_5KKnXRvLKz_e4CffLqYPVrZzkoNwM8nSwzfecUKVvJvlzNefvl8c3o9u-aXxW8Z3Lrq
CitedBy_id crossref_primary_10_1556_2054_2022_00195
crossref_primary_10_17744_mehc_42_4_03
crossref_primary_10_1016_j_pnpbp_2009_04_010
crossref_primary_10_1016_j_neuron_2022_12_031
crossref_primary_10_1177_070674371105600304
crossref_primary_10_1016_j_neubiorev_2018_02_004
crossref_primary_10_1017_S1461145707007900
crossref_primary_10_1017_S0033291723001514
crossref_primary_10_1080_00029157_2021_1943299
crossref_primary_10_1080_00207144_2014_931177
crossref_primary_10_1097_YPG_0b013e32833a212f
crossref_primary_10_1080_00223891_2011_627966
crossref_primary_10_1016_j_bandc_2014_10_008
crossref_primary_10_1017_S0033291715002901
crossref_primary_10_3389_fphar_2018_00897
crossref_primary_10_1055_a_1721_2914
crossref_primary_10_1080_08870446_2017_1357814
crossref_primary_10_1093_pnasnexus_pgae066
crossref_primary_10_1093_sleep_32_12_1629
crossref_primary_10_1098_rspb_2007_0876
crossref_primary_10_1016_j_concog_2019_05_008
crossref_primary_10_1016_j_concog_2017_07_009
crossref_primary_10_1080_15287390801985687
crossref_primary_10_4103_psychiatry_IndianJPsychiatry_129_18
crossref_primary_10_1017_S0033291723003653
crossref_primary_10_1093_nc_niae038
crossref_primary_10_1016_j_nsa_2024_104092
crossref_primary_10_4000_12xrc
crossref_primary_10_1177_1745691619895047
crossref_primary_10_1016_j_bbr_2010_07_003
crossref_primary_10_3389_fnhum_2014_00771
crossref_primary_10_1371_journal_pone_0030800
crossref_primary_10_1016_j_jad_2024_02_089
crossref_primary_10_1016_j_biopsycho_2012_09_007
crossref_primary_10_1371_journal_pone_0211023
crossref_primary_10_1177_0269881120981384
crossref_primary_10_1007_s11469_024_01253_9
crossref_primary_10_1016_j_bbr_2011_08_012
crossref_primary_10_3389_fpsyg_2018_01424
crossref_primary_10_1021_acsptsci_1c00014
crossref_primary_10_1016_j_bandc_2012_06_001
crossref_primary_10_1016_j_cobeha_2016_10_008
crossref_primary_10_1038_tpj_2011_10
crossref_primary_10_1080_00029157_2020_1865869
crossref_primary_10_1093_nc_niaa004
crossref_primary_10_1177_0269881117725915
crossref_primary_10_1016_j_neulet_2006_07_030
crossref_primary_10_1177_0269881120959637
crossref_primary_10_1080_13674676_2011_637913
crossref_primary_10_2174_1745017900905010009
crossref_primary_10_1007_s00213_014_3714_z
crossref_primary_10_1002_hbm_22688
crossref_primary_10_1016_j_paid_2016_02_078
crossref_primary_10_1016_j_ynirp_2023_100171
crossref_primary_10_1038_sj_mp_4001814
crossref_primary_10_1038_s41598_021_01209_2
Cites_doi 10.1097/00041444-200010040-00006
10.1016/S0361-9230(01)00646-3
10.1037/0022-3514.72.4.929
10.1016/S0893-133X(01)00333-5
10.1001/archpsyc.59.1.85
10.1001/archpsyc.60.9.889
10.1073/pnas.0732088100
10.1097/00001756-199812010-00024
10.1016/j.pharmthera.2003.11.002
10.1002/1096-8628(20001204)96:6<831::AID-AJMG27>3.0.CO;2-K
10.1016/S0140-6736(96)90939-3
10.1002/jnr.10173
10.1186/1471-2202-3-14
10.1176/ajp.156.9.1456
10.1111/1467-6494.05018
10.1162/089892902760191117
10.1037/h0036681
10.1002/1096-8628(20001204)96:6<771::AID-AJMG14>3.0.CO;2-T
10.1016/S1053-8100(02)00046-6
10.1097/00008571-199606000-00007
10.1080/00207149408409352
10.1016/S0920-9964(03)00183-X
10.1176/appi.ajp.160.11.1965
10.2466/PR0.83.6.387-391
10.1097/00008571-199702000-00009
10.1080/02791072.2002.10399962
10.1038/sj.npp.1395318
ContentType Journal Article
Copyright Copyright © 2005 Wiley‐Liss, Inc.
(c) 2005 Wiley-Liss, Inc.
Copyright_xml – notice: Copyright © 2005 Wiley‐Liss, Inc.
– notice: (c) 2005 Wiley-Liss, Inc.
DBID BSCLL
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1002/ajmg.b.30197
DatabaseName Istex
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1552-485X
EndPage 32
ExternalDocumentID 15965969
10_1002_ajmg_b_30197
AJMG30197
ark_67375_WNG_5SKXDPGP_N
Genre shortCommunication
Journal Article
GroupedDBID .55
.GA
.Y3
05W
0R~
10A
1L6
1OC
23M
31~
33P
4.4
51W
51X
52N
52O
52P
52S
52T
52W
52X
53G
5GY
5VS
7PT
8-1
8-4
8-5
8UM
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABIJN
ABIVO
ABJNI
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACPOU
ACPRK
ACXBN
ACXQS
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
BDRZF
BFHJK
BRXPI
BSCLL
BY8
CS3
D-F
DCZOG
DPXWK
DR2
DRFUL
DRSTM
EBS
EJD
F00
F01
F04
F5P
FEDTE
G-S
GNP
GODZA
HBH
HGLYW
HHY
HHZ
HVGLF
IX1
KQQ
LATKE
LAW
LEEKS
LH4
LOXES
LP6
LP7
LUTES
LYRES
MEWTI
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
OIG
P2P
P2W
P4D
QB0
QRW
ROL
RWI
SUPJJ
UB1
V2E
W99
WIH
WJL
WQJ
WRC
WXSBR
X7M
XG1
XV2
AAHQN
AAMNL
AANHP
AAYCA
ACRPL
ACYXJ
ADNMO
AFWVQ
ALVPJ
AAYXX
AEYWJ
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c4027-98176e2d1ed811cc7a8970f700e7b3d0db7c189d350610692b0c2f67bf08f0ac3
IEDL.DBID DR2
ISSN 1552-4841
IngestDate Fri Jul 11 01:40:01 EDT 2025
Fri Jun 20 17:44:13 EDT 2025
Thu Apr 24 22:59:17 EDT 2025
Tue Jul 01 04:31:20 EDT 2025
Wed Jan 22 16:45:36 EST 2025
Wed Oct 30 09:47:46 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License http://doi.wiley.com/10.1002/tdm_license_1.1
(c) 2005 Wiley-Liss, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4027-98176e2d1ed811cc7a8970f700e7b3d0db7c189d350610692b0c2f67bf08f0ac3
Notes ArticleID:AJMG30197
ark:/67375/WNG-5SKXDPGP-N
istex:A1E72E12AC58789A8B6009B1788EE5F4B489FA35
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 15965969
PQID 68076101
PQPubID 23479
PageCount 4
ParticipantIDs proquest_miscellaneous_68076101
pubmed_primary_15965969
crossref_primary_10_1002_ajmg_b_30197
crossref_citationtrail_10_1002_ajmg_b_30197
wiley_primary_10_1002_ajmg_b_30197_AJMG30197
istex_primary_ark_67375_WNG_5SKXDPGP_N
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 5 August 2005
PublicationDateYYYYMMDD 2005-08-05
PublicationDate_xml – month: 08
  year: 2005
  text: 5 August 2005
  day: 05
PublicationDecade 2000
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
– name: United States
PublicationTitle American journal of medical genetics. Part B, Neuropsychiatric genetics
PublicationTitleAlternate Am. J. Med. Genet
PublicationYear 2005
Publisher Wiley Subscription Services, Inc., A Wiley Company
Publisher_xml – name: Wiley Subscription Services, Inc., A Wiley Company
References Crawford HJ. 1994. Brain dynamics and hypnosis-attentional and disattentional processes. Int J Clin Exp Hypn 42: 204-232.
Turecki G, Brière R, Dewar K, Antonetti T, Lesage AD, Séguin M, Chawky N, Vanier C, Alda M, Joober R, Benkelfat C, Rouleau GA. 1999. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry 156: 1456-1458.
Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Baebler A, Vogel H, Hell D. 1998. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9: 3897-3902.
Tellegen A. 1982. Brief manual for the multidimensional personality questionnaire. Unpublished manuscript. Minneapolis: University of Minnesota.
Tellegen A, Atkinson G. 1974. Openness to absorbing and self-altering experiences ("absorption"), a trait related to hypnotic susceptibility. J Abnorm Psychol 83: 268-277.
Syvänen AC, Tilgmann C, Rinne J, Ulmanen I. 1997. Genetic polymorphism of catechol-O-methyltransferase (COMT): Correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics 7: 65-71.
Nichols DE. 2004. Hallucinogens. Pharmacol Ther 101: 131-181.
Donnelly JP. 1998. A continuum model of personality disorder. Psychol Rep: 83: 387-391.
Goodman N. 2002. The serotonergic system and mysticism: Could LSD and the nondrug-induced mystical experience share common neural mechanisms? J Psychoactive Drugs 34: 263-272.
Borg J, Andrée B, Soderstrom H, Farde L. 2003. The serotonin system and spiritual experiences. Am J Psychiatry 160: 1965-1969.
Dietrich A. 2003. Functional neuroanatomy of altered states of consciousness: The transient hypofrontality hypothesis. Conscious Cogn 12: 231-256.
Lichtenberg P, Bachner-Melman R, Gritsenko I, Ebstein RP. 2000. Exploratory association study between catechol-O-methyltransferase (COMT) high/low enzyme activity polymorphism and hypnotizability. Am J Med Genet (Neuropsychiatr Genet) 96: 771-774.
Polesskaya OO, Sokolov BP. 2002. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 67: 812-822.
Ando J, Ono Y, Yoshimura K, Onoda N, Shinohara M, Kanba S, Asai M. 2002. The genetic structure of Cloninger's seven-factor model of temperament and character in a Japanese sample. J Pers 70: 583-609.
Finkel D, McGue M. 1997. Sex differences and nonadditivity in heritability of the Multidimensional Personality Questionnaire Scales. J Pers Soc Psychol 72(4): 929-938.
Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. 1996. Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6: 243-250.
Williams J, Spurlock G, McGuffin P, Mallet J, Nothen MM, Gill M, Aschauer H, Nylander PO, Macciardi F, Owen MJ. 1996. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet 347: 1294-1296.
Fan J, Fossella J, Sommer T, Wu Y, Posner MI. 2003. Mapping the genetic variation of executive attention onto brain activity. Proc Natl Acad Sci USA 100: 7406-7411.
Cloninger CR, Przybeck TR, Svrakic DM, Wetzel RD. 1994. The temperament and character inventory: A guide to its development and use. St Louis: Washington University Center for Psychobiology of Personality.
Comings DE, Gonzales N, Saucier G, Johnson JP, MacMurray JP. 2000. The DRD4 gene and the spiritual transcendence scale of the character temperament index. Psychiatr Genet 10: 185-189.
Ritz T, Dahme B. 1995. Die Absorption-Skala: Konzeptuelle Aspekte, psychometrische Kennwerte und Dimensionalität einer deutschsprachigen Adaptation [The Absorption Scale: Conceptual aspects, psychometric properties, and dimensionality of a German adaptation]. Diagnostica 41: 53-61.
Aghajanian GK, Marek GJ. 1999. Serotonin and hallucinogens. Neuropsychopharmacology 21: 16S-23S.
Porras G, Di Matteo V, Fracasso C, Lucas G, De Deurwaerdere P, Caccia S, Esposito E, Spampinato U. 2002. 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26: 311-324.
Raz A, Shapiro T. 2002. Hypnosis and neuroscience: A cross talk between clinical and cognitive research. Arch Gen Psychiatry 59: 85-90.
Rainville P, Hofbauer RK, Bushnell MC, Duncan FH, Price DD. 2002. Hypnosis modulates activity in brain structures involved in the regulation of consciousness. J Cogn Neurosci 14: 887-901.
Vollenweider FX, Geyer MA. 2001. A systems model of altered consciousness: Integrating natural and drug-induced psychosis. Brain Res Bull 56: 495-507.
Bondy B, Kuznik J, Baghai T, Schule C, Zwanzger P, Minov C, de Jonge S, Rupprecht R, Meyer H, Engel RR, Eisenmenger W, Ackenheil M. 2000. Lack of association of serotonin-2A receptor gene polymorphism (T102C) with suicidal ideation and suicide. Am J Med Genet 96: 831-835.
Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT. 2004. Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res 67: 53-62.
Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS, Goldman D, Weinberger DR. 2003. Executive subprocesses in working memory: Relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 60: 889-896.
Fossella J, Sommer T, Fan J, Wu Y, Swanson JM, Pfaff DW, Posner MI. 2002. Assessing the molecular genetics of attention networks. BMC Neuroscience 3: 14.
2004; 101
2002; 14
2002; 59
2002; 34
2004; 67
2002; 3
1999; 21
1994
1998; 83
1997; 7
1994; 42
2003; 12
1996; 347
1995; 41
2002; 26
1997; 72
1974; 83
2000; 10
2002; 67
2000; 96
2003; 160
2002; 70
1982
1999; 156
2003; 60
2001; 56
2003; 100
1996; 6
1998; 9
Cloninger (10.1002/ajmg.b.30197-BIB6) 1994
Nichols (10.1002/ajmg.b.30197-BIB18) 2004; 101
Vollenweider (10.1002/ajmg.b.30197-BIB29) 1998; 9
Bondy (10.1002/ajmg.b.30197-BIB4) 2000; 96
Vollenweider (10.1002/ajmg.b.30197-BIB28) 2001; 56
Fossella (10.1002/ajmg.b.30197-BIB13) 2002; 3
Turecki (10.1002/ajmg.b.30197-BIB27) 1999; 156
Goldberg (10.1002/ajmg.b.30197-BIB14) 2003; 60
Polesskaya (10.1002/ajmg.b.30197-BIB19) 2002; 67
Tellegen (10.1002/ajmg.b.30197-BIB26) 1974; 83
Fan (10.1002/ajmg.b.30197-BIB11) 2003; 100
Syvänen (10.1002/ajmg.b.30197-BIB24) 1997; 7
Aghajanian (10.1002/ajmg.b.30197-BIB2) 1999; 21
Finkel (10.1002/ajmg.b.30197-BIB12) 1997; 72
Goodman (10.1002/ajmg.b.30197-BIB15) 2002; 34
Raz (10.1002/ajmg.b.30197-BIB22) 2002; 59
Crawford (10.1002/ajmg.b.30197-BIB8) 1994; 42
Rainville (10.1002/ajmg.b.30197-BIB21) 2002; 14
Ritz (10.1002/ajmg.b.30197-BIB23) 1995; 41
Tellegen (10.1002/ajmg.b.30197-BIB25) 1982
Comings (10.1002/ajmg.b.30197-BIB7) 2000; 10
Lachman (10.1002/ajmg.b.30197-BIB16) 1996; 6
Lichtenberg (10.1002/ajmg.b.30197-BIB17) 2000; 96
Borg (10.1002/ajmg.b.30197-BIB5) 2003; 160
Williams (10.1002/ajmg.b.30197-BIB30) 1996; 347
Dietrich (10.1002/ajmg.b.30197-BIB9) 2003; 12
Porras (10.1002/ajmg.b.30197-BIB20) 2002; 26
Donnelly (10.1002/ajmg.b.30197-BIB10) 1998; 83
Ando (10.1002/ajmg.b.30197-BIB3) 2002; 70
Abdolmaleky (10.1002/ajmg.b.30197-BIB1) 2004; 67
References_xml – reference: Ritz T, Dahme B. 1995. Die Absorption-Skala: Konzeptuelle Aspekte, psychometrische Kennwerte und Dimensionalität einer deutschsprachigen Adaptation [The Absorption Scale: Conceptual aspects, psychometric properties, and dimensionality of a German adaptation]. Diagnostica 41: 53-61.
– reference: Nichols DE. 2004. Hallucinogens. Pharmacol Ther 101: 131-181.
– reference: Williams J, Spurlock G, McGuffin P, Mallet J, Nothen MM, Gill M, Aschauer H, Nylander PO, Macciardi F, Owen MJ. 1996. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet 347: 1294-1296.
– reference: Bondy B, Kuznik J, Baghai T, Schule C, Zwanzger P, Minov C, de Jonge S, Rupprecht R, Meyer H, Engel RR, Eisenmenger W, Ackenheil M. 2000. Lack of association of serotonin-2A receptor gene polymorphism (T102C) with suicidal ideation and suicide. Am J Med Genet 96: 831-835.
– reference: Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS, Goldman D, Weinberger DR. 2003. Executive subprocesses in working memory: Relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 60: 889-896.
– reference: Cloninger CR, Przybeck TR, Svrakic DM, Wetzel RD. 1994. The temperament and character inventory: A guide to its development and use. St Louis: Washington University Center for Psychobiology of Personality.
– reference: Comings DE, Gonzales N, Saucier G, Johnson JP, MacMurray JP. 2000. The DRD4 gene and the spiritual transcendence scale of the character temperament index. Psychiatr Genet 10: 185-189.
– reference: Fan J, Fossella J, Sommer T, Wu Y, Posner MI. 2003. Mapping the genetic variation of executive attention onto brain activity. Proc Natl Acad Sci USA 100: 7406-7411.
– reference: Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. 1996. Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6: 243-250.
– reference: Crawford HJ. 1994. Brain dynamics and hypnosis-attentional and disattentional processes. Int J Clin Exp Hypn 42: 204-232.
– reference: Donnelly JP. 1998. A continuum model of personality disorder. Psychol Rep: 83: 387-391.
– reference: Finkel D, McGue M. 1997. Sex differences and nonadditivity in heritability of the Multidimensional Personality Questionnaire Scales. J Pers Soc Psychol 72(4): 929-938.
– reference: Rainville P, Hofbauer RK, Bushnell MC, Duncan FH, Price DD. 2002. Hypnosis modulates activity in brain structures involved in the regulation of consciousness. J Cogn Neurosci 14: 887-901.
– reference: Turecki G, Brière R, Dewar K, Antonetti T, Lesage AD, Séguin M, Chawky N, Vanier C, Alda M, Joober R, Benkelfat C, Rouleau GA. 1999. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry 156: 1456-1458.
– reference: Vollenweider FX, Geyer MA. 2001. A systems model of altered consciousness: Integrating natural and drug-induced psychosis. Brain Res Bull 56: 495-507.
– reference: Polesskaya OO, Sokolov BP. 2002. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 67: 812-822.
– reference: Porras G, Di Matteo V, Fracasso C, Lucas G, De Deurwaerdere P, Caccia S, Esposito E, Spampinato U. 2002. 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26: 311-324.
– reference: Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Baebler A, Vogel H, Hell D. 1998. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9: 3897-3902.
– reference: Aghajanian GK, Marek GJ. 1999. Serotonin and hallucinogens. Neuropsychopharmacology 21: 16S-23S.
– reference: Ando J, Ono Y, Yoshimura K, Onoda N, Shinohara M, Kanba S, Asai M. 2002. The genetic structure of Cloninger's seven-factor model of temperament and character in a Japanese sample. J Pers 70: 583-609.
– reference: Lichtenberg P, Bachner-Melman R, Gritsenko I, Ebstein RP. 2000. Exploratory association study between catechol-O-methyltransferase (COMT) high/low enzyme activity polymorphism and hypnotizability. Am J Med Genet (Neuropsychiatr Genet) 96: 771-774.
– reference: Raz A, Shapiro T. 2002. Hypnosis and neuroscience: A cross talk between clinical and cognitive research. Arch Gen Psychiatry 59: 85-90.
– reference: Borg J, Andrée B, Soderstrom H, Farde L. 2003. The serotonin system and spiritual experiences. Am J Psychiatry 160: 1965-1969.
– reference: Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT. 2004. Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res 67: 53-62.
– reference: Tellegen A. 1982. Brief manual for the multidimensional personality questionnaire. Unpublished manuscript. Minneapolis: University of Minnesota.
– reference: Tellegen A, Atkinson G. 1974. Openness to absorbing and self-altering experiences ("absorption"), a trait related to hypnotic susceptibility. J Abnorm Psychol 83: 268-277.
– reference: Goodman N. 2002. The serotonergic system and mysticism: Could LSD and the nondrug-induced mystical experience share common neural mechanisms? J Psychoactive Drugs 34: 263-272.
– reference: Syvänen AC, Tilgmann C, Rinne J, Ulmanen I. 1997. Genetic polymorphism of catechol-O-methyltransferase (COMT): Correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics 7: 65-71.
– reference: Dietrich A. 2003. Functional neuroanatomy of altered states of consciousness: The transient hypofrontality hypothesis. Conscious Cogn 12: 231-256.
– reference: Fossella J, Sommer T, Fan J, Wu Y, Swanson JM, Pfaff DW, Posner MI. 2002. Assessing the molecular genetics of attention networks. BMC Neuroscience 3: 14.
– volume: 101
  start-page: 131
  year: 2004
  end-page: 181
  article-title: Hallucinogens
  publication-title: Pharmacol Ther
– volume: 9
  start-page: 3897
  year: 1998
  end-page: 3902
  article-title: Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action
  publication-title: NeuroReport
– volume: 14
  start-page: 887
  year: 2002
  end-page: 901
  article-title: Hypnosis modulates activity in brain structures involved in the regulation of consciousness
  publication-title: J Cogn Neurosci
– volume: 26
  start-page: 311
  year: 2002
  end-page: 324
  article-title: 5‐HT2A and 5‐HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum
  publication-title: Neuropsychopharmacology
– volume: 42
  start-page: 204
  year: 1994
  end-page: 232
  article-title: Brain dynamics and hypnosis—attentional and disattentional processes
  publication-title: Int J Clin Exp Hypn
– volume: 100
  start-page: 7406
  year: 2003
  end-page: 7411
  article-title: Mapping the genetic variation of executive attention onto brain activity
  publication-title: Proc Natl Acad Sci USA
– volume: 67
  start-page: 812
  year: 2002
  end-page: 822
  article-title: Differential expression of the “C” and “T” alleles of the receptor gene in the temporal cortex of normal individuals and schizophrenics
  publication-title: J Neurosci Res
– volume: 56
  start-page: 495
  year: 2001
  end-page: 507
  article-title: A systems model of altered consciousness: Integrating natural and drug‐induced psychosis
  publication-title: Brain Res Bull
– volume: 60
  start-page: 889
  year: 2003
  end-page: 896
  article-title: Executive subprocesses in working memory: Relationship to catechol‐ ‐methyltransferase Val158Met genotype and schizophrenia
  publication-title: Arch Gen Psychiatry
– volume: 83
  start-page: 387
  year: 1998
  end-page: 391
  article-title: A continuum model of personality disorder
  publication-title: Psychol Rep
– year: 1994
– volume: 7
  start-page: 65
  year: 1997
  end-page: 71
  article-title: Genetic polymorphism of catechol‐ ‐methyltransferase (COMT): Correlation of genotype with individual variation of S‐COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland
  publication-title: Pharmacogenetics
– volume: 70
  start-page: 583
  year: 2002
  end-page: 609
  article-title: The genetic structure of Cloninger's seven‐factor model of temperament and character in a Japanese sample
  publication-title: J Pers
– volume: 67
  start-page: 53
  year: 2004
  end-page: 62
  article-title: Meta‐analysis of association between the T102C polymorphism of the receptor gene and schizophrenia
  publication-title: Schizophr Res
– year: 1982
– volume: 347
  start-page: 1294
  year: 1996
  end-page: 1296
  article-title: Association between schizophrenia and T102C polymorphism of the 5‐hydroxytryptamine type 2a‐receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group
  publication-title: Lancet
– volume: 21
  start-page: 16S
  year: 1999
  end-page: 23S
  article-title: Serotonin and hallucinogens
  publication-title: Neuropsychopharmacology
– volume: 34
  start-page: 263
  year: 2002
  end-page: 272
  article-title: The serotonergic system and mysticism: Could LSD and the nondrug‐induced mystical experience share common neural mechanisms?
  publication-title: J Psychoactive Drugs
– volume: 10
  start-page: 185
  year: 2000
  end-page: 189
  article-title: The DRD4 gene and the spiritual transcendence scale of the character temperament index
  publication-title: Psychiatr Genet
– volume: 160
  start-page: 1965
  year: 2003
  end-page: 1969
  article-title: The serotonin system and spiritual experiences
  publication-title: Am J Psychiatry
– volume: 83
  start-page: 268
  year: 1974
  end-page: 277
  article-title: Openness to absorbing and self‐altering experiences (“absorption”), a trait related to hypnotic susceptibility
  publication-title: J Abnorm Psychol
– volume: 72
  start-page: 929
  issue: 4
  year: 1997
  end-page: 938
  article-title: Sex differences and nonadditivity in heritability of the Multidimensional Personality Questionnaire Scales
  publication-title: J Pers Soc Psychol
– volume: 6
  start-page: 243
  year: 1996
  end-page: 250
  article-title: Human catechol‐ ‐methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders
  publication-title: Pharmacogenetics
– volume: 156
  start-page: 1456
  year: 1999
  end-page: 1458
  article-title: Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide
  publication-title: Am J Psychiatry
– volume: 59
  start-page: 85
  year: 2002
  end-page: 90
  article-title: Hypnosis and neuroscience: A cross talk between clinical and cognitive research
  publication-title: Arch Gen Psychiatry
– volume: 96
  start-page: 831
  year: 2000
  end-page: 835
  article-title: Lack of association of serotonin‐2A receptor gene polymorphism ( ) with suicidal ideation and suicide
  publication-title: Am J Med Genet
– volume: 41
  start-page: 53
  year: 1995
  end-page: 61
  article-title: Die Absorption‐Skala: Konzeptuelle Aspekte, psychometrische Kennwerte und Dimensionalität einer deutschsprachigen Adaptation [The Absorption Scale: Conceptual aspects, psychometric properties, and dimensionality of a German adaptation]
  publication-title: Diagnostica
– volume: 3
  start-page: 14
  year: 2002
  article-title: Assessing the molecular genetics of attention networks
  publication-title: BMC Neuroscience
– volume: 96
  start-page: 771
  year: 2000
  end-page: 774
  article-title: Exploratory association study between catechol‐ ‐methyltransferase (COMT) high/low enzyme activity polymorphism and hypnotizability
  publication-title: Am J Med Genet (Neuropsychiatr Genet)
– volume: 12
  start-page: 231
  year: 2003
  end-page: 256
  article-title: Functional neuroanatomy of altered states of consciousness: The transient hypofrontality hypothesis
  publication-title: Conscious Cogn
– volume: 10
  start-page: 185
  year: 2000
  ident: 10.1002/ajmg.b.30197-BIB7
  publication-title: Psychiatr Genet
  doi: 10.1097/00041444-200010040-00006
– volume: 56
  start-page: 495
  year: 2001
  ident: 10.1002/ajmg.b.30197-BIB28
  publication-title: Brain Res Bull
  doi: 10.1016/S0361-9230(01)00646-3
– volume: 72
  start-page: 929
  year: 1997
  ident: 10.1002/ajmg.b.30197-BIB12
  publication-title: J Pers Soc Psychol
  doi: 10.1037/0022-3514.72.4.929
– volume: 26
  start-page: 311
  year: 2002
  ident: 10.1002/ajmg.b.30197-BIB20
  publication-title: Neuropsychopharmacology
  doi: 10.1016/S0893-133X(01)00333-5
– volume: 59
  start-page: 85
  year: 2002
  ident: 10.1002/ajmg.b.30197-BIB22
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.59.1.85
– volume: 60
  start-page: 889
  year: 2003
  ident: 10.1002/ajmg.b.30197-BIB14
  publication-title: Arch Gen Psychiatry
  doi: 10.1001/archpsyc.60.9.889
– volume: 100
  start-page: 7406
  year: 2003
  ident: 10.1002/ajmg.b.30197-BIB11
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0732088100
– volume-title: The temperament and character inventory: A guide to its development and use
  year: 1994
  ident: 10.1002/ajmg.b.30197-BIB6
– volume: 9
  start-page: 3897
  year: 1998
  ident: 10.1002/ajmg.b.30197-BIB29
  publication-title: NeuroReport
  doi: 10.1097/00001756-199812010-00024
– volume: 101
  start-page: 131
  year: 2004
  ident: 10.1002/ajmg.b.30197-BIB18
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2003.11.002
– volume: 96
  start-page: 831
  year: 2000
  ident: 10.1002/ajmg.b.30197-BIB4
  publication-title: Am J Med Genet
  doi: 10.1002/1096-8628(20001204)96:6<831::AID-AJMG27>3.0.CO;2-K
– volume: 347
  start-page: 1294
  year: 1996
  ident: 10.1002/ajmg.b.30197-BIB30
  publication-title: Lancet
  doi: 10.1016/S0140-6736(96)90939-3
– volume: 67
  start-page: 812
  year: 2002
  ident: 10.1002/ajmg.b.30197-BIB19
  publication-title: J Neurosci Res
  doi: 10.1002/jnr.10173
– volume: 3
  start-page: 14
  year: 2002
  ident: 10.1002/ajmg.b.30197-BIB13
  publication-title: BMC Neuroscience
  doi: 10.1186/1471-2202-3-14
– volume: 156
  start-page: 1456
  year: 1999
  ident: 10.1002/ajmg.b.30197-BIB27
  publication-title: Am J Psychiatry
  doi: 10.1176/ajp.156.9.1456
– volume: 70
  start-page: 583
  year: 2002
  ident: 10.1002/ajmg.b.30197-BIB3
  publication-title: J Pers
  doi: 10.1111/1467-6494.05018
– volume-title: Brief manual for the multidimensional personality questionnaire. Unpublished manuscript
  year: 1982
  ident: 10.1002/ajmg.b.30197-BIB25
– volume: 14
  start-page: 887
  year: 2002
  ident: 10.1002/ajmg.b.30197-BIB21
  publication-title: J Cogn Neurosci
  doi: 10.1162/089892902760191117
– volume: 83
  start-page: 268
  year: 1974
  ident: 10.1002/ajmg.b.30197-BIB26
  publication-title: J Abnorm Psychol
  doi: 10.1037/h0036681
– volume: 96
  start-page: 771
  year: 2000
  ident: 10.1002/ajmg.b.30197-BIB17
  publication-title: Am J Med Genet (Neuropsychiatr Genet)
  doi: 10.1002/1096-8628(20001204)96:6<771::AID-AJMG14>3.0.CO;2-T
– volume: 12
  start-page: 231
  year: 2003
  ident: 10.1002/ajmg.b.30197-BIB9
  publication-title: Conscious Cogn
  doi: 10.1016/S1053-8100(02)00046-6
– volume: 6
  start-page: 243
  year: 1996
  ident: 10.1002/ajmg.b.30197-BIB16
  publication-title: Pharmacogenetics
  doi: 10.1097/00008571-199606000-00007
– volume: 42
  start-page: 204
  year: 1994
  ident: 10.1002/ajmg.b.30197-BIB8
  publication-title: Int J Clin Exp Hypn
  doi: 10.1080/00207149408409352
– volume: 67
  start-page: 53
  year: 2004
  ident: 10.1002/ajmg.b.30197-BIB1
  publication-title: Schizophr Res
  doi: 10.1016/S0920-9964(03)00183-X
– volume: 160
  start-page: 1965
  year: 2003
  ident: 10.1002/ajmg.b.30197-BIB5
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.160.11.1965
– volume: 41
  start-page: 53
  year: 1995
  ident: 10.1002/ajmg.b.30197-BIB23
  publication-title: Diagnostica
– volume: 83
  start-page: 387
  year: 1998
  ident: 10.1002/ajmg.b.30197-BIB10
  publication-title: Psychol Rep
  doi: 10.2466/PR0.83.6.387-391
– volume: 7
  start-page: 65
  year: 1997
  ident: 10.1002/ajmg.b.30197-BIB24
  publication-title: Pharmacogenetics
  doi: 10.1097/00008571-199702000-00009
– volume: 34
  start-page: 263
  year: 2002
  ident: 10.1002/ajmg.b.30197-BIB15
  publication-title: J Psychoactive Drugs
  doi: 10.1080/02791072.2002.10399962
– volume: 21
  start-page: 16s
  year: 1999
  ident: 10.1002/ajmg.b.30197-BIB2
  publication-title: Neuropsychopharmacology
  doi: 10.1038/sj.npp.1395318
SSID ssj0030577
Score 2.0607357
Snippet Absorption represents a disposition to experience altered states of consciousness characterized by intensively focused attention. It is correlated with...
SourceID proquest
pubmed
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 29
SubjectTerms absorption trait
Adult
Alleles
Attention - physiology
Catechol O-Methyltransferase - genetics
dopamine
Epistasis, Genetic
Female
Gene Frequency
Genotype
Hallucinations - genetics
Hallucinations - physiopathology
Humans
Male
molecular genetics
Polymorphism, Genetic
Receptor, Serotonin, 5-HT2A - genetics
Schizophrenia - genetics
Schizophrenia - physiopathology
serotonin
T102C
Title Evidence for a common biological basis of the absorption trait, hallucinogen effects, and positive symptoms: Epistasis between 5-HT2a and COMT polymorphisms
URI https://api.istex.fr/ark:/67375/WNG-5SKXDPGP-N/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fajmg.b.30197
https://www.ncbi.nlm.nih.gov/pubmed/15965969
https://www.proquest.com/docview/68076101
Volume 137B
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbhMxFLVQEYgNj_IKTy-ADZnU8_B4zK7qI1FRQgWpyM6yZzxQ2sxEmQkirPgEvoCP40u41zNJKQIk2Hnht4_tY_v6XEKeJBy9FJnE00YyL4ItD0Ii8ALNWRrHUvMQPycPR_HgKDqY8El74YZ_YRp9iPWFG84Mt17jBNem2joTDdUfpu96pgcAlfiZ3A9jlM7ffb1WjwIkO8eLKDLmRUnkt3bvkHzr58TndqSL2Lmffkc3z7NXt_3sXyNqVfHG6uSkt6hNL_38i6bj_7fsOrnaMlO63UDpBrlgi01yqfFVudwkl4ftK_xN8m3lipQC46WaQv4AZtroOeGgU9gbjyta5hToJYViy7lbmSg6pKi7FB24LCCvEtBLW4uSLtVFRhsbso-WVsvprC6n1Qu6N0OKi_m1NmWUf__ydTAOtEux82o4hmSnyykU8v64mla3yNH-3nhn4LV-HrwUTq_Ck4kvYhtkvs0S309ToRMpWC4Ys8KEGcuMSP1EZiEH8sFiGRiWBnksTM6SnOk0vE02irKwdwnNo1CwzDKrdRJJa43kQHHgVJYH2kqWdcjz1VirtBVBx6afqka-OVDY-coo1_kd8nQde9aIf_wh3jMHm3UkPT9BgznB1dtRX_E3Lye7h_1DNeqQxytcKZjG-DajC1suKhUneKHE_A6508DtrECOmo-x7JCuA81fa6K2D4Z9F7r3b9HvkytOlBaNYfgDslHPF_Yh0K3aPHKT6gcVdSe-
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LctMwFNVAOzw2PAqU8KoWwIY4lR3Lsth1-khom9CBdJqdkGy5lDZxJk4YwopP4Av4OL6Ee2UnpQwww7DTQm8dSUfS1bmEPI05eikysaeNZF4IWx6EROAFmrMkiqTmTfyc3OlG7cNwt8_7lZ9T_AtT6kMsLtxwZrj1Gic4Xkivn6uG6g-D44ZpAEKluEyWQ-AaePraerPQjwIsO9eLKDPmhXHoV5bvkH7959QX9qRl7N5PvyOcF_mr24B2bpJ386qXdienjenENJLPv6g6_kfbbpEbFTmlGyWabpNLdrhCrpTuKmcr5Gqneoi_Q77NvZFSIL1UUygA8ExLSSccdwrb40lB84wCw6TaFPnYLU4UfVJM6hR9uEwhrxwATCujkjrVw5SWZmQfLS1mg9EkHxQv6fYIWS7mV5mVUf79y9d2L9AuxebrTg-Snc0GUMj7k2JQ3CWHO9u9zbZXuXrwEjjACk_GvohskPo2jX0_SYSOpWCZYMwK00xZakTixzJtcuAfLJKBYUmQRcJkLM6YTpr3yNIwH9r7hGZhU7DUMqt1HEprjeTAcuBglgXaSpbWyIv5YKuk0kHHpp-pUsE5UNj5yijX-TXybBF7VOp__CHec4ebRSQ9PkWbOcHVUbel-Nu9_tZB60B1a2RtDiwFMxmfZ_TQ5tNCRTHeKTG_RlZLvJ0XyFH2MZI1Uneo-WtN1MZup-VCD_4t-hq51u519tX-q-7eQ3LdadSibQx_RJYm46l9DOxrYp64GfYDeVMr3Q
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LctMwFNVAO3TY8Cgv86oWwIY4lR-yLHadtkloSchAOs1OI9kylDZ2JnYYwopP4Av4OL6EK9lJKQPMwE4LvXUkHUlX5yL0JKbGS5GKXak4cUPY8iDEfNeXlCRRxCUNzOfk_iDqHYUHYzpuLtzMX5haH2J14WZmhl2vzQSfptn2uWio_DB511ZtAChnl9F6GAGZMKTozUo-CqBsPS8alTE3jEOvMXyH9Ns_p76wJa2b3v30O755kb7a_adzHYllzWuzk9P2vFLt5PMvoo7_37Qb6FpDTfFOjaWb6JLON9GV2lnlYhNt9Jtn-Fvo29IXKQbKiyWG_AHNuBZ0MqOOYXM8KXGRYeCXWKqymNmlCRuPFFULGw8uc8irAPjixqSkhWWe4tqI7KPG5WIyrYpJ-QLvTw3HNfk1RmWYfv_ytTfypU2x-7o_gmRniwkU8v6knJS30VFnf7TbcxtHD24Cx1fm8thjkfZTT6ex5yUJkzFnJGOEaKaClKSKJV7M04AC-yAR9xVJ_CxiKiNxRmQS3EFreZHrewhnYcBIqomWMg651opT4DhwLMt8qTlJHfR8OdYiaVTQTdPPRK3f7AvT-UIJ2_kOerqKPa3VP_4Q75mFzSqSnJ0aizlGxfGgK-jbw_HesDsUAwdtLXElYB6bxxmZ62Jeiig2N0rEc9DdGm7nBVIj-hhxB7UsaP5aE7Fz0O_a0P1_i76FNoZ7HfHq5eDwAbpqBWqNYQx9iNaq2Vw_AupVqcd2fv0A3VoqjA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evidence+for+a+common+biological+basis+of+the+Absorption+trait%2C+hallucinogen+effects%2C+and+positive+symptoms%3A+epistasis+between+5-HT2a+and+COMT+polymorphisms&rft.jtitle=American+journal+of+medical+genetics.+Part+B%2C+Neuropsychiatric+genetics&rft.au=Ott%2C+Ulrich&rft.au=Reuter%2C+Martin&rft.au=Hennig%2C+Juergen&rft.au=Vaitl%2C+Dieter&rft.date=2005-08-05&rft.issn=1552-4841&rft.volume=137B&rft.issue=1&rft.spage=29&rft_id=info:doi/10.1002%2Fajmg.b.30197&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1552-4841&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1552-4841&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1552-4841&client=summon